Liang Yan, Quan Huili, Bu Tong, Li Xuedong, Liu Xingang, Wang Songsong, He Dian, Jia Qingzhong, Zhang Yang
Materia Medica Development Group, Institute of Medicinal Chemistry, Lanzhou University School of Pharmacy, Lanzhou, China.
The Fourth Hospital of Shijiazhuang, Shijiazhuang, China.
Front Chem. 2021 Feb 18;9:614154. doi: 10.3389/fchem.2021.614154. eCollection 2021.
Fascaplysin is a natural marine product originating from sponges, attracting widespread attention due to its potential inhibitory activities against CDK4. However, its clinical application has been largely limited because of serious adverse effects caused by planar skeleton. To reduce the serious adverse effects, 18 tetrahydro-β-carboline analogs (compounds 6a-i and 7a-i) were designed and synthesized via breaking the planarity of fascaplysin, and the biological activities of the synthesized compounds were evaluated by MTT assay and CDK4/CycD3 enzyme inhibition assay. The title compounds showed varying degrees of inhibitory activities, especially the cytotoxicity of compound 6c against HeLa cells (IC = 1.03 ± 0.19 μM) with quite weak cytotoxicity toward the normal cells WI-38 (IC = 311.51 ± 56.06 μM), and the kinase inhibition test indicated that compound 6c was a potential CDK4 inhibitor. In order to further compare the action mechanisms of planar and nonplanar molecules on CDK4, the studied complexes of CDK4 bound with fascaplysin and three representative compounds (compound 6a-c) with bioactivities gradient were constructed by molecular docking and further verified through molecular dynamic simulation, which identified the key residues contributing to the ligands' binding. By comparing the binding modes of the constructed systems, it could be found that the residues contributing significantly to compound 6c's binding were highly consistent with those contributing significantly to fascaplysin's binding. Through the design, synthesis of the nonplanar fascaplysin derivatives, and binding mechanism analysis, some valuable hints for the discovery of antitumor drug candidates could be provided.
法卡普利辛是一种源自海绵的天然海洋产物,因其对细胞周期蛋白依赖性激酶4(CDK4)具有潜在抑制活性而受到广泛关注。然而,由于其平面骨架导致的严重不良反应,其临床应用在很大程度上受到限制。为了减少严重的不良反应,通过破坏法卡普利辛的平面性设计并合成了18种四氢-β-咔啉类似物(化合物6a-i和7a-i),并通过MTT法和CDK4/CycD3酶抑制试验评估了合成化合物的生物活性。标题化合物表现出不同程度的抑制活性,特别是化合物6c对HeLa细胞的细胞毒性(IC = 1.03 ± 0.19 μM),而对正常细胞WI-38的细胞毒性相当弱(IC = 311.51 ± 56.06 μM),激酶抑制试验表明化合物6c是一种潜在的CDK4抑制剂。为了进一步比较平面和非平面分子对CDK4的作用机制,通过分子对接构建了CDK4与法卡普利辛以及三种具有生物活性梯度的代表性化合物(化合物6a-c)结合的研究复合物,并通过分子动力学模拟进一步验证,确定了有助于配体结合的关键残基。通过比较构建系统的结合模式,可以发现对化合物6c结合有显著贡献的残基与对法卡普利辛结合有显著贡献的残基高度一致。通过非平面法卡普利辛衍生物的设计、合成以及结合机制分析,可以为发现抗肿瘤候选药物提供一些有价值的线索。